» Articles » PMID: 29472719

Epigenetic Heterogeneity Affects the Risk of Relapse in Children with T(8;21)RUNX1-RUNX1T1-rearranged AML

Abstract

The somatic translocation t(8;21)(q22;q22)/RUNX1-RUNX1T1 is one of the most frequent rearrangements found in children with standard-risk acute myeloid leukemia (AML). Despite the favorable prognostic role of this aberration, we recently observed a higher than expected frequency of relapse. Here, we employed an integrated high-throughput approach aimed at identifying new biological features predicting relapse among 34 t(8;21)-rearranged patients. We found that the DNA methylation status of patients who suffered from relapse was peculiarly different from that of children maintaining complete remission. The epigenetic signature, made up of 337 differentially methylated regions, was then integrated with gene and protein expression profiles, leading to a network, where cell-to-cell adhesion and cell-motility pathways were found to be aberrantly activated in relapsed patients. We identified most of these factors as RUNX1-RUNX1T1 targets, with Ras Homolog Family Member (RHOB) overexpression being the core of this network. We documented how RHOB re-organized the actin cytoskeleton through its downstream ROCK-LIMK-COFILIN axis: this increases blast adhesion by stress fiber formation, and reduces mitochondrial apoptotic cell death after chemotherapy treatment. Altogether, our data show an epigenetic heterogeneity within t(8;21)-rearranged AML patients at diagnosis able to influence the program of the chimeric transcript, promoting blast re-emergence and progression to relapse.

Citing Articles

Preclinical Evaluation of a Novel Small Molecule Inhibitor of LIM Kinases (LIMK) CEL_Amide in Philadelphia-Chromosome Positive () Acute Lymphoblastic Leukemia (ALL).

Berrou J, Dupont M, Djamai H, Adiceam E, Parietti V, Kaci A J Clin Med. 2022; 11(22).

PMID: 36431240 PMC: 9692768. DOI: 10.3390/jcm11226761.


RUNX1/CEBPA Mutation in Acute Myeloid Leukemia Promotes Hypermethylation and Indicates for Demethylation Therapy.

Romanova E, Zubritskiy A, Lioznova A, Ogunleye A, Golotin V, Guts A Int J Mol Sci. 2022; 23(19).

PMID: 36232714 PMC: 9569612. DOI: 10.3390/ijms231911413.


Small Non-Coding RNAs in Leukemia.

Balatti V, Croce C Cancers (Basel). 2022; 14(3).

PMID: 35158777 PMC: 8833386. DOI: 10.3390/cancers14030509.


Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid Leukemia.

Tregnago C, Benetton M, Da Ros A, Borella G, Longo G, Polato K Front Pharmacol. 2022; 12:820191.

PMID: 35153769 PMC: 8830338. DOI: 10.3389/fphar.2021.820191.


DNA Methylation Signatures Predict Cytogenetic Subtype and Outcome in Pediatric Acute Myeloid Leukemia (AML).

Krali O, Palle J, Backlin C, Abrahamsson J, Noren-Nystrom U, Hasle H Genes (Basel). 2021; 12(6).

PMID: 34200630 PMC: 8229099. DOI: 10.3390/genes12060895.